gammanorm
- Name:
gammanorm
- Company:
Octapharma Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/06/18
(Click to Download) Summary of Product Characteristics last updated on medicines.ie: 15/8/2018
Click on this link to Download PDF directly
Octapharma Ltd
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name albunorm 20% | Active Ingredients Human Albumin |
| Medicine Name albunorm 5% | Active Ingredients Human Albumin |
| Medicine Name gammanorm | Active Ingredients Human Normal Immunoglobulin |
| Medicine Name LG-octaplas solution for infusion | Active Ingredients Human Plasma Proteins |
| Medicine Name Nuwiq powder and solvent for solution for injection | Active Ingredients simoctocog alfa |
| Medicine Name Octaplex 1000 IU coagulation factor IX per vial, powder and solvent for solution for infusion | Active Ingredients Human Prothrombin Complex |
| Medicine Name Octaplex 500 IU coagulation factor IX per vial, powder and solvent for solution for infusion | Active Ingredients Human Prothrombin Complex |
| Medicine Name Panzyga 100 mg/ml solution for infusion | Active Ingredients Human Normal Immunoglobulin |
| Medicine Name Wilate powder and solvent for solution for injection | Active Ingredients Factor VIII, von Willebrand factor |
Items Per Page :
1 - 0 of 9 items.Total: Infinity pages
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 15 August 2018 SmPC
Reasons for updating
- File format updated to PDF
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 11 June 2018 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 11 June 2018 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - marketing authorisation number
Updated on 7 February 2018 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 10 - Date of revision of the text
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 4.1 - Therapeutic indications
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Section 4.1: More detail given regarding therapeutic indications$0- Section 4.2: Rapid push has been added as a method of administration (i.e. subcutaneous infusion using a syringe)$0$0- Section 4.4: More detail has been given regarding Contraindications $0$0- Section 4.6: Crosses the placenta increasingly during third trimester$0$0- Section 4.7: May impair ability to drive$0$0- Section 4.8: Undesirable effects has been re-written, with addition of new tabulated list of adverse reactions$0$0- Section 5.1: Addition of a new clinical study$0
Updated on 7 February 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 7 February 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 7 February 2018 PIL
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - driving and using machines
- Change to section 3 - dose and frequency
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 1 March 2016 PIL
Reasons for updating
- Change of manufacturer
Updated on 10 November 2015 SmPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
- Change to improve clarity and readability
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 - change of wording to one side effect$04.8 - updated HPRA contact information$0$010 - Updated date of revision of text$0
Updated on 11 February 2015 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8: Inclusion of Thromboembolic events as Vary rare ADR
Section 10: Updated revision of text.Updated on 11 February 2015 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 14 March 2014 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
None provided